Edit this postLupin came into existence following the amalgamation of Lupin laboratories with Lupin Chemicals. Its activities include pharmaceuticals, bulk drugs and formulations, fermentation, bio-technology, natural products and agro chemicals. Its Lupin division offers solutions in the respiratory segment that covers anti-TB, anti-asthma (inhalation segment), anti-infectives, anti-allergies and supportive therapy products. The top six products in the API basket viz., cephalexin and cefaclor (anti-lnfectives), 7ADCA and 7ACCA (cephalosporin intermediates), ethambutol and rifampicin (anti-TB) cover nearly 80% of API sales to the semi regulated markets. Lisinopril (cardiovascular) forms the core API sales to the regulated markets. The biggest brand of the company is R-Cinex. The Lupin division dominates the anti-TB segment with a market share of 45%. Its finished dosages business has outperformed the market growth rate by nearly two-and-half times.
The company filed for 14 ANDAs and 15 DMFs and now has four molecules in clinical trials. It raised its R&D expenditure to 7.2% of net sales in 2004-2005 to create commercially viable intellectual property for the company. Its AKT-4 now occupies a 7.5% market share in the 4-drug combipack segment. Lupin has set its focus on broad-spectrum anti-bacterials, anti-asthma and diabetic research. The company has plans to enter new non-conventional route of drug administration. Synthesis of drugs involving complex chemistry/technology has been identified for process development research. New herbal leads for new indications have been identified for further development. It also plans to tap emerging opportunities for licensing-out products.
